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Heart transplantation (HTx) improves symptoms and prolongs life in advanced heart failure (HF), but organ supply is limited. In recent years,
mechanical circulatory support and specifically implantable left ventricular assist devices (LVADs) have undergone technical improvements,
and outcomes have improved dramatically. Left ventricular assist devices are now viable options for patients with severe HF as bridge to
transplantation, destination therapy, or as bridge to recovery. Many believe that LVADs may soon provide outcomes similar to, or better
than, HTx, launching a new era of end-stage HF management. The key to improving outcomes is patient selection, but the field is changing
rapidly and guidelines and consensus are limited. This review summarizes recent reports of predictors of poor outcomes and provides an
overview of selection for LVAD therapy.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Keywords Left ventricular assist device † Mechanical circulatory support † Heart transplantation † Advanced heart failure †
Patient selection
Advanced heart failure: scope
of the problem
Systolic heart failure (HF) is a growing pandemic with an incidence
of 0.15–0.5% and a prevalence of 1–2% in the western world.1 –3
Advanced HF affects 10% of the HF population and is associated
with a dismal quality of life, recurrent hospitalizations, and a mor-
tality of up to 50% at 1 year.1 –4 Medical arms in left ventricular
assist device (LVAD) trials have generally been inotrope-
dependent and have had 1-year mortalities of over 75%.5,6
Heart transplantation (HTx) is associated with nearly 90%
1-year survival, 60% 10-year survival, and 95% freedom from symp-
toms and activity limitations in survivors throughout the
follow-up.7 But because of organ shortage and long waiting
times, 10% of transplant listed patients die each year,8 and many
more deteriorate, making transplantation higher risk, and as Eric
Rose once stated, ‘epidemiologically trivial’. Therefore, recent
advances in mechanical circulatory support (MCS), specifically
implantable LVAD therapy, are providing alternatives for patients
waiting for HTx [bridge to transplantation (BTT)] and also for
patients who are ineligible for HTx [destination therapy (DT)] or
who are anticipated to experience recovery after left ventricular
unloading [bridge to recovery (BTR)].
Left ventricular assist devices
First generation positive displacement pulsatile LVADs best mimic
natural conditions but second generation continuous flow pumps
have smaller size, simpler implantation, more limited blood con-
tacting area, fewer moving parts and lack valves, air vents and com-
pliance chambers, providing for longer durability with reduced
risks for thromboembolism, infection, and malfunction. Third gen-
eration devices utilize impeller or centrifugal motors that are
mechanically, magnetically, or hydro-suspended. The sophisticated
motor and suspension features minimize complications and allow
support for many years and potentially decades,9 further expanding
the candidate pool for LVAD therapy.
Current estimates of the number of LVAD candidates range
from 10 0003 to 200 00010,11 patients in the USA. These patients
would benefit both in terms of prolonged survival and improved
symptoms and quality of life. Cost-effectiveness is reasonable at
US $36 000–86 000 per life year or quality-adjusted life year in
broad populations.12 Left ventricular assist device therapy receives
a class IIa level C for BTT and class IIb level C for DT from the
ESC13 and class IIa level B for DT from ACC/AHA.14
As technology and long-term outcomes continue to improve,
there is indeed potential for LVAD therapy to replace
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transplantation. All patients with New York Heart Association
(NYHA) class III– IV/stage D HF are now potential candidates for
LVAD support, but risks and benefits will vary considerably
between patients. Thus, knowledge among cardiologists and early
referral to transplant/LVAD centres are critical. Favourable out-
comes require proper patient selection and strategic timing of
implantation and an LVAD programme with a multi-disciplinary
team of cardiologists, cardiac surgeons, anaesthetists, perfusionists,
nurses, social workers, and other professionals with knowledge of
the numerous complex patient- and device-specific aspects before,
during, and after implantation.
Indications and contraindications
for left ventricular assist devices
Cardiac surgeons and HF specialists are continually improving can-
didate selection for LVAD support. Previously, patients with
chronic HF in NYHA class IV and impending cardiogenic shock
and/or multi-organ failure3,15– 18 were the main candidates for
long-term LVAD. However, with improving device technology, sur-
gical skill, and patient management, we are moving toward implan-
tation in a less ill patient cohort. About 80–90% of LVADs are
implanted in transplant candidates who are not expected to
survive until transplant or who are deemed too sick for transplant
or with potentially reversible transplant contraindications
(BTT).19,20 Destination therapy is for selected patients who are
not eligible for HTx, either due to age or comorbidities, for
whom pump therapy is meant to be a permanent, life-long, form
of left ventricular replacement. The DT population represents a
growing share of implants and offers the greatest potential for
improvements in HF morbidity and mortality. For some individuals,
the candidacy dichotomization is not clear, either for medical or
social reasons, and the term ‘bridge to decision’ has been
applied. Finally, BTR is offered for rare patients where LVAD
unloading is expected to lead to sufficient reverse remodelling
for clinical recovery and the possibility of explantation.
However, the above patient labels are increasingly becoming
arbitrary. Up to 17% of DT patients subsequently undergo HTx4
and many BTT patients subsequently become ineligible for HTx.
Recovery is possible but highly unpredictable.21 –24 Some patients
have the LVAD explanted despite incomplete recovery because
of device-related complications.
The risk prediction tools and criteria for HTx-listing, including the
peak VO2 and the Heart Failure Survival Score (HFSS), are well vali-
dated and generally agreed upon.13,25–27 In contrast, there are no vali-
dated selection criteria and indeed no consensus when it comes to
candidate selection for LVAD, and selection relies instead on clinical
status, inotrope dependence, and invasive haemodynamic par-
ameters.3,5,6,15–18,28–33 With worsening clinical status, the need for
LVAD increases but so does the peri-operative risk, and optimal oper-
ative timing becomes difficult (see what follows).
The main goals of LVAD therapy are to improve symptoms,
quality of life, and prognosis. But other important goals are to
stabilize or reverse organ dysfunction or pulmonary vascular
hypertension to increase the likelihood of a successful transplant,
to prevent progressive right ventricular dysfunction which would
make a future LVAD high risk or contraindicated, or to provide
early unloading to prevent remodelling in a cardiomyopathy with
hopes for recovery. Expected waiting time for HTx, which are
highly variable between different regions and dependent on body
size, blood type and panel reactive antibodies, as well as local con-
ditions with regard to types of devices available, practice and
expertise, regulation and ethical views also play important roles
and make decisions to and timing of implant difficult.34
Risks and benefits may be difficult for patients to grasp. Patient
preferences are highly variable but in one study LVAD implantation
was preferred if life expectancy without LVAD was 6–12 months
or less and activity was limited to less than one block walking.35
This level of severity is similar to that where most clinicians
would recommend LVAD implantation (Table 1). The urgency of
acute implantation and/or bridging from short-term mechanical
support often preclude a complete medical and psychosocial
assessment, but discontinuation of device support due to unde-
tected conditions is rare and outcomes are similar to elective
implantations with complete pre-operative assessments.36
An important effort to consolidate experience in the MCS field [left
(LVAD), right (RVAD), and bi-ventricular (BiVAD) assist devices and
total artificial hearts (TAHs)] is the NIH-sponsored Interagency Reg-
istry for Mechanically Assisted Circulatory Support (INTERMACS).
Currently, 97 sites and 1959 patients are registered.37,38 European
efforts to establish a similar registry are under way. INTERMACS
has devised seven levels of severity of HF (Table 2).
Table 1 describes these authors’ proposed indications and con-
traindications for LVAD therapy, derived from international con-
sensus and entry criteria in clinical studies.3,5,6,15 –18,28– 33,39,40
Outcomes after left ventricular
assist device
Outcomes after LVAD placement are dependent on the era of
implant, surgical experience, device and patient characteristics, and
time after implant. Operative mortality in well-selected patients has
improved to about 5–10%;30,41 survival to transplant has improved
from 33 to 71% in one series;29 and 1-year overall survival has
improved from about 50%5,6,19 to nearly 80%.20,28,30,42,43
The peri-operative period is crucial, with the vast majority of deaths
occurring prior to hospital discharge.4 The most important compli-
cations peri-operatively are multi-organ failure, neurologic or periph-
eral embolic events, bleeding, infection and sepsis, and acute RV
failure (see what follows).44,45 In the longer term, complications
include embolic or haemorrhagic stroke, the progression of pre-
existing or de novo development of RV failure, human leucocyte
antigen (HLA) sensitization, renal insufficiency, device failure or infec-
tion requiring transplantation, explantation or replacement, gastroin-
testinal bleeding, and psychological maladjustment.6,19,28–30,39,45,46
Left ventricular unloading generally improves sustained ventricular
arrhythmia burden, but a short-term increase in arrhythmias has
been documented.47,48 Ventricular arrhythmias of up to 12 days have
reportedly been tolerated on LVAD support,49 but decompensation
with end-organ dysfunction and syncope are not infrequent.
Three key factors that have contributed to improved patient out-
comes include advances in MCS technology, surgical technique and
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experience, and better patient selection. Modern continuous flow
devices28,30,42,43,46,50 have equal51 or better survival, less bleeding,52
infection52,53 and mechanical failure54 and shorter duration of inten-
sive care,51 but possibly more risk of thromboembolism54 than
older pulsatile devices.5,6,29 One-year survival in subjects undergoing
HeartMate XVE (Thoratec Corporation, Pleasanton, CA, USA)
implantation for DT in the REMATCH trial was 52%.5 While the
patient cohort was different and interpretation is more difficult
Table 1 Proposed indications and contraindications for left ventricular assist device
Indications
Strong indication. Bridge to transplant, destination or bridge to recovery. All must apply
NYHA IV for 60–90 days
Maximal tolerated medical therapy and CRT/ICD if indicated
Chronic inotrope dependence
LVEF ,25%
PCWP 20 mm Hg
SBP 80–90 mm Hg or CI 2 L/min/m2 or declining renal or RV functiona
Moderate indication. More often destination than bridge to transplant or recovery.b All must apply
NYHA IV for 30 days
Maximal tolerated medical therapy and CRT/ICD if indicated
Intermittent inotrope dependence
LVEF ,25%
Peak VO2 ,12 mL/kg/min
Indication to enable HTx. Either must apply
PVR .5 Woods units, secondary to chronic HF and expected to reverse after LVAD
GFR ,25–30 mL/min/1.73 m2, secondary to chronic HF and likely to improve after LVAD
Conversion from short-term MCS to long-term LVAD
Contraindications
Some may be relative, especially as technology improves.
Acute cardiogenic shock or arrest with uncertain neurologic statusc
Irreversible contraindication to HTx if destination or recovery is not the aim
Non-systolic HF
Co-existing illness with life expectancy ,2 years
Terminal severe comorbidity; e.g. renal disease (haemodialysis or creatinine .2.5–5 mg/dL), metastatic or advanced cancer, severe liver disease
(spontaneous INR .2.5, bilirubin .5 mg/dL, or cirrhosis or portal hypertension), severe lung disease (severe obstructive or restrictive disease or
home O2), severe peripheral artery disease, or unresolved stroke or severe neuromuscular disorder
Active uncontrolled systemic infection or significant risk of infection
Active severe bleeding
Chronic platelet count ,50 000  109 per L
Antibody-confirmed heparin induced thrombocytopenia
Right HF not secondary to left HFa
Severe RV dysfunction or MOFa
Moderate or severe aortic insufficiency that will not be corrected
Mechanical aortic valve that will not be converted to bioprosthesis
LV thrombus that will not be removed
Anatomical considerations such as hypertrophic cardiomyopathy, large ventricular septal defect, or congenital heart disease
Intolerance to the anticoagulant regimen specific to device
Body surface area ,1.2–1.5 m2 or other dimensional or technical limitation
Inability to grasp risks and benefits and provide informed consent
Psychosocial limitations, e.g. inability to comply with medical regimen or device and driveline maintenance
or inability of patient or companion to maintain LVAD operation and interpret alarms
NYHA, New York Heart Association; CRT, cardiac resynchronization therapy; ICD, intra-cardiac defibrillator; LVEF, left ventricular ejection fraction; PCWP, pulmonary capillary
wedge pressure; SBP, systolic blood pressure; CI, cardiac index; RV, right ventricle; PVR, pulmonary vascular resistance; GFR, glomerular filtration rate; MCS, mechanical
circulatory support; MOF, multi-organ failure; HF, heart failure; HTx, heart transplantation; INR, international normalized ratio.
aDeclining renal function and MOF may make HTx or LVAD higher risk; declining RV function and MOF may make LVAD higher risk and require BiVAD or TAH (see below).
bPatients considered for HTx30 generally require a worse clinical status (haemodynamic derangements) than patients considered for destination therapy.5 The former group
would generally not receive LVAD on a moderate indication since the risks of LVAD outweigh the benefits as HTx before severe deterioration is possible, whereas the latter
derive no benefit from deferring LVAD implantation.
cThese patients may be considered for short-term MCS.
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because of competing outcomes, in a prospective study of 133 sub-
jects from 26 US centres undergoing HeartMate II implantation as a
BTT, survival was 68% at 1 year30 and when the study was extended
to 281 patients, survival was 72% at 18 months,43 about half of whom
were transplanted and half alive on device. Of 571 HeartMate II
implants for variable indications from 64 European institutions,
1-year survival was 69%.42 A clinical trial comparing HeartMate I
(VE/XVE) to HeartMate II was recently stopped early because of
better outcomes with HeartMate II.40
The HeartMate VE or XVE has now been implanted in more
than 5000 patients.55 The importance of experience was illustrated
in REMATCH, where patients in the LVAD group enrolled in
1998–99 had 44% 1-year and 21% 2-year survival, respectively,
compared with 59 and 38% for those enrolled in 2000–01.56 In
a post-REMATCH DT cohort with HeartMate XVE (Thoratec),
1-year survival was 62%.57
Selection and risk scores with
focus on overall outcomes
The most important factor for improving patient outcomes after
LVAD is careful patient selection. Reviews of patient selec-
tion15,58–61 have generally not included recent risk models4,62–68
or risk factors.19,29,69 –86
Patients should be assigned one of the seven INTERMACS
levels.20,61,81 These levels and their corresponding prognosis
(Table 2) have not been tested or validated in actual patient sets but
are helpful for overall clinical assessment. Individual predictors of
poor operative outcome include age,19,29,80,86 female gender,19 dia-
betes19 prior cardiac surgery,29,70 pre-existing right HF,80 respiratory
failure and septicaemia,80 pre-operative extracorporeal membrane
oxygenation83 or mechanical ventilation,19 renal dysfunction,19,82–85
elevated blood urea nitrogen,70 coagulopathy and lower platelet and
higher white blood cell counts,19 and worse INTERMACS levels.20,81
In addition, there are several risk scores that predict overall out-
comes (Table 3). The Lietz–Miller destination therapy risk score
(DTRS) analysed 45 baseline parameters and outcomes in DT
patients in the post-REMATCH era. Laboratory, haemodynamic,
and clinical predictors generated a score that divided candidates
into low-, medium-, and high-risk strata.4 Klotz et al.68 analysed 100
pre-operative parameters in a variety of device recipients and found
34 univariate and 13 multi-variate risk factors for intensive care unit
mortality. They devised a score with high-, medium-, and low-risk
strata. The Columbia University/Cleveland Clinic risk factor selection
scale (RFSS)62 and revised screening scale (RSS)63 analysed predictors
in BTT recipients, and Holman et al.67 in the INTERMACS database.
These studies and risk models have several important limit-
ations. They were derived mainly in patients receiving first gener-
ation pulsatile devices; they do not consider under-represented
populations such as women, African Americans, and those who
due to body size limitations were ineligible for the larger first gen-
eration devices. Comorbidities such as diabetes or severe cachexia
or obesity were under-represented but have theoretical reasons to
fare worse and may preclude transplant. Psychosocial factors and
outcomes are not considered. Recidivism of drug and/or alcohol
and return to work are unknown. Finally, data are available only
on short-term and not longer term outcomes.
Importantly, these models also lack prospective independent
validation. We dichotomized 145 LVAD recipients according to
published thresholds for several scores and observed hazard
ratios for 6-month death, renal failure, and RVAD need ranging
from 2.1 to 9.4 when comparing high- to low-risk strata and posi-
tive and negative predictive values for death ranging from 23 to
43% and 88 to 91%, respectively.87 Thus, another major limitation
is that while low-risk patients identified by the models are likely
low risk, patients with high-risk scores are not necessarily truly
high risk. As we move toward less ill patients, these scores will
need re-evaluation.
Selection and risk scores with
focus on right ventricular failure
In the long term, LV unloading and decreases in LV filling pressures
and subsequently pulmonary vascular resistance (PVR) often lead
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Table 2 INTERMACS levels and outcomes
Level Description Number of implants Number of deaths Estimated 1-year survival (%)
1 Critical cardiogenic shock 481 121 65
2 Progressive decline 514 102 72
3 Stable but inotrope-dependent 172 20 82
4 Recurrent advanced HF 116 16 75
5 Exertion intolerant 78 16 72
6 Exertion limited 78 16 72
7 Advanced NYHA III 78 16 72
Overall 1361 275 73
Data includes all types of MCS, including LVAD, RVAD, BiVAD, and TAH.
Implant dates 23 June 2006 to 31 March 2009.
Follow-up presumed until 31 March 2009.
One-year survival is estimated from Kaplan–Meier curves available in reference.20
NYHA, New York Heart Association.
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Table 3 Risk factors for complications or mortality post left ventricular assist device
Study Columbia University/






Therapy Risk Score (DTRS)
P INTERMACS RR Muenster P
Reference Oz et al.62 Rao et al.63 Lietz et al.4 Holman et al.67 Klotz et al.68
Device HM IP or HM VE HM VE HM XVE Variable (including 5
RVADs, 77 BiVADs, and
24 TAH)
Variable
n 56 130 222 420 241
Risk factors Urine output , 30 cc/h 3 Mechanical ventilation 4 Platelets count  148 000/mL 7 Ascites 2.0 Pre-operative transfusions of .10
units RBC and/or .10 units FFP
6
CVP . 16 2 Post-cardiotomy shock 2 Albumin  3.3 g/dL 5 INTERMACS level 1 1.6 Inotropes 5
Mechanical ventilation 2 Pre-operative LVAD 2 INR . 1.1 4  age (60 vs. 50) 1.4 Lactate . 3 mg/dL 5
PT . 16 2 CVP . 16 1 Vasodilator therapy 4 Bilirubin . 1 mg/dL 1.5 LDH . 500 and/or CK . 200 and/
or troponin I . 20
ng/mL
5
Re-sternotomy 1 PT . 16 1 mPAP  25 3 BiVAD implant 2.1 C-reactive protein . 8 and/or
WBC . 13
4
AST . 45 2 TAH implant 2.4 Re-sternotomy 4
Haematocrit  34% 2 Pre-operative mechanical support 4
BUN . 51 2 Mechanical ventilation 3
No inotropes 2 Creatinine . 1.5 mg/dL and/or





Heart rate . 100 1
Platelets , 100 000/mL 1
Haemoglobin , 12 g/dL and/or
haematocrit . 35%
1
Age . 50 1
Outcome Score . 5 points ! operative
mortality 67%
Score . 5 vs.  5 points !
operative mortality 46 vs. 12%
Score and 1-year survival: 0–8 points:
81%, 9–16 points: 62%, 17–19 points:
28%, . 19 points: 11%
RR is for 6-month mortality Score and ICU mortality:
 15 points: 15.8%,
16–30 points: 48.2%,
. 30 points: 65.2%
Limitations/
comments
Short follow-up; no multivariate
analysis; no data on
underrepresented populations
Short follow-up; no data on
underrepresented populations
No patients with mechanical ventilation,





Short follow-up; variable devices;
no data on underrepresented
populations
HM IP, HeartMate implantable pneumatic; HM VE, HeartMate vented electric; CVP, central venous pressure (mmHg); PT, prothrombin time (s); P, points; HM XVE, HeartMate XVE; RR, relative risk; INR, international normalized ratio; mPAP,
mean pulmonary artery pressure (mmHg); AST, aspartate aminotransferase (U/mL); BUN, blood urea nitrogen (U/dL); BiVAD, bi-ventricular assist device; TAH, total artificial heart; RBC, red blood cells; FFP, fresh frozen plasma; LDH, lactate






to improved RV function after LVAD. But in the early post-
operative period, numerous complex mechanisms may contribute
to RV failure. These include sudden increases in cardiac output,
leading to increased venous return and thus RV preload, septal
shift causing increased RV wall stress, and increased pulmonary
vasoreactivity in the setting of cardiopulmonary bypass, blood
transfusions, and inflammation, leading to increased RV afterload.65
The incidence of RV failure ranges from 7 to 50% depending on
definition and study.17– 19,64– 66,69,71,72 Right ventricular failure
leads to liver and renal failure, lymphoedema and ascites, and
underfilling of the LV and the pump, with potential for arrhythmia
and cardiogenic shock. Peri-operative mortality increases from 19
to 43% and survival both to and after HTx becomes worse,65
although it has been suggested that increased risk is primarily in
the peri-operative period and that chronic RV failure post LVAD
may not impair successful bridging to transplantation.88 The
impact of long-term LVAD support on RV function and the intrin-
sic progression of RV cardiomyopathy warrants study and may be
an obstacle in the era of ‘permanent’ LVAD support.
There is limited prospective data but anecdotal evidence suggests
that the risk of RV failure can be decreased by pre-operative optimiz-
ation of nutrition, haemodynamics, and organ function and minimiz-
ation of RV pre-load, with parenteral nutrition, inotropes, and
intra-aortic balloon pump (IABP). Other steps to lower the risk of
RV failure include peri-operative minimization of bleeding and trans-
fusion needs, effective coronary perfusion and avoidance of cardiople-
gia, avoidance of surgical RV injury and RV distension, prophylactic
RVAD89,90 and inotropes, tricuspid annuloplasty, early cessation of
positive pressure ventilation and RV afterload reduction with nitric
oxide18,91 nitroprusside, and perhaps prostanoids, endothelin recep-
tor antagonists and phosphodiesterase inhibitors. Nonetheless, esca-
lating inotropic therapy and therapeutic mechanical RV assist often
become necessary.
Most important, again, is careful selection. For those accus-
tomed to HTx selection, assessing RV failure risk post LVAD is
counterintuitive. A key favourable prognostic factor is the ability
of the RV to generate pressure and forward flow; thus high pul-
monary artery pressure (PAP) is favourable, whereas high central
venous pressure (CVP) and pre-operative RV failure and large tri-
cuspid regurgitation are detrimental. We identified vasopressor
requirement, aspartate aminotransferase 80 IU/L, bilirubin 
2.0 mg/dL, and creatinine  2.3 mg/dL as independent predictors
or RV failure and constructed an RV failure risk score with an
area under the receiver–operating characteristic curve of 0.73.65
Fitzpatrick et al.64 identified systolic blood pressure 96 mmHg,
cardiac index 2.2 L/min/m2, RV stroke work index
0.25 mmHg L/m2, creatinine 1.9 mg/dL, severe pre-operative
RV dysfunction and previous cardiac surgery as independent risk
factors and constructed an algorithm for predicting RVAD need
with .80% sensitivity and specificity. Numerous additional predic-
tors have been identified, many of which directly or indirectly
reflect RV function (Table 4).64– 66,69,71 –73,76,78,79,92 More severe
INTERMACS patient profiles more often have biventricular
failure and markers of RV failure such as liver dysfunction and
ascites, are more likely to require BiVAD or TAH, and have
worse outcomes.81,93 Interpretation of these data is clouded by
the fact that most publications identified only univariate predictors
and describe exclusively18,39,69,71–73,76,78,92 or mostly first gener-
ation devices.19,65 Although RV failure appears less common with
second generation devices,28,30 there are also fewer parameters
to predict it.94
Timing of implantation
With limited data to suggest otherwise, many clinicians implant LV
support only when patients are severely ill (Table 1). But longer
durability and fewer complications with modern devices as well
as recognition of the unpredictability of HF deterioration and the
importance of being in good clinical and RV status has lead to a
shift toward less catastrophically ill patients, such as INTERMACS
3–4 or prior to chronic inotrope dependence. Up to 40% of stable
HTx listed patients destabilize to require high-urgency HTx or
emergency LVAD.95 Earlier implantation, before RV and multi-
organ failure, leads to better outcomes (see under risk scores
above). This is a favoured strategy for DT. Yet, LVADs are still
associated with 5–10% peri-operative mortality30,41 and consider-
able morbidity and cost, and a HTx-listed patient in good clinical
status and a short estimated waiting time may be better served
by conservative management.
An emerging issue in BTT patients is whether to implant an LVAD
before the institution of chronic inotrope support, a decision that
depends on the relative effects of inotropes and LVADs on survival
up to and after HTx. Survival on the waiting list depends on the like-
lihood of being transplanted within a reasonable time.34 A vast
majority of patients implanted to date have been inotrope-
dependent.5,6,17,19,28–30,39,45,46,96 Inotrope dependence is associated
with more than 50% mortality at 6 months97 and the medical arm in
REMATCH5 and INTrEPID6 had 76 and 89% mortality at 1 year,
respectively. However, in HTx-listed patients protected with a defi-
brillator, inotropes may improve or preserve organ function and
clinical status until HTx,98,99 and pre-HTx inotropes do not impair
post-HTx prognosis.7 A pre-HTx LVAD is associated with the com-
plications of the LVAD itself, may provoke HLA sensitization which
can impact heart transplant candidacy, and entails re-sternotomy at
the time of HTx. In the ISHLT registry, patients with pre-HTx LVAD
fared worse post-HTx.7 But this registry does not account for selec-
tion bias, era of implant, patient characteristics, and other confound-
ing factors. In fact, other studies suggest a neutral45,100 or
favourable17,29,39,101,102 effect of pre-HTx LVAD on post-HTx out-
comes. Furthermore, many patients on inotropes eventually need
an LVAD anyway, for successful bridging to transplantation.103
One attempt at withdrawing inotropes may be attempted,33 but
the need for repeat inotropes should prompt consideration for
LVAD implantation. Timing also depends on aim. For inotrope-
dependent DT candidates, LVAD implantation should not be
deferred, as chronic inotrope use does not prolong survival. It is
also important to recognize that poor tolerance of evidence-based
pharmacologic therapy, repeat hospitalizations, escalating inotrope,
or even pressor needs, or end organ dysfunction, are more impor-
tant integrated criteria for LVAD than single haemodynamic par-
ameters. Most importantly, outcomes are better for stable
patients entering an operative procedure than for subjects who
are in extremis.
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Summary
Long-term LVAD therapy is evolving into an effective and reason-
ably cost-effective therapy for a growing population of patients
with advanced HF. Left ventricular assist devices provide dramatic
left ventricular unloading and increased cardiac output and
improve end-organ function. Left ventricular assist device patients
now enjoy a 1-year survival of nearly 80% and reap improvement in
symptoms and quality of life from NYHA IV to II.
The most important factor in improving outcomes is proper
selection. Selecting patients for LVAD will require a comprehensive
assessment of indications and contraindications (Table 1), risk
factors, and scores for overall outcomes (Table 3) and outcomes
with regard to RV failure (Table 4), as well as optimal timing.
However, LVADs are still associated with an approximately 5–
10% peri-operative mortality and frequent short- and long-term
complications including right ventricular failure, bleeding, throm-
boembolic and haemorrhagic stroke, infection, and device failure.
Improved technology, experience, and patient selection have
improved outcomes, but also make published risk prediction
studies obsolete. Thus, more prospective multicentre studies are
needed to assess risk in a broad range of subjects undergoing
LVAD implantation. Furthermore, as we embark on an era of
true long-term support, more studies are needed to predict long-
term outcomes.
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